Chardan Capital Reaffirms Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Chardan Capital restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $225.00 target price on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reissued a neutral rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Wells Fargo & Company reduced their price objective on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating for the company in a report on Friday, February 16th. The Goldman Sachs Group lowered Alnylam Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for the company from $230.00 to $173.00 in a research note on Friday, February 16th. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a neutral rating in a report on Thursday, February 1st. Finally, William Blair reaffirmed an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $215.88.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $151.22 on Friday. The stock has a market cap of $19.13 billion, a PE ratio of -56.43 and a beta of 0.41. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88. The firm’s 50-day simple moving average is $149.51 and its 200 day simple moving average is $165.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The business’s revenue was up 54.8% on a year-over-year basis. During the same period in the prior year, the company earned ($1.40) earnings per share. As a group, analysts predict that Alnylam Pharmaceuticals will post -4.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its position in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Quent Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $38,000. Robeco Institutional Asset Management B.V. raised its position in Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the period. Finally, GAMMA Investing LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $52,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.